Eurazeo to buy C2S from Bridgepoint

The transaction is set to take place in 2018, according to press reports. 

Seller Bridgepoint made the original investment from Bridgepoint Development Capital I (BDC I) in 2011. 

Eurazeo is a Euronext-listed investment company with assets under management (AUM) of approximately €7bn, of which €1bn is from third parties.

According to French daily Capital Finance, GPs Sagard and Chequers Capital competed with Eurazeo for the investment.

In 2011, Bridgepoint acquired a 51% stake in French clinics operator C2S for an undisclosed amount. Management held the remainder of the shares. BDC I is a £300m fund that typically invests €10-75m in companies valued between €20-150m, according to unquote" data.

BDC was attracted by the strong growth prospects of the private clinics market in France. It believes C2S will now be able to consolidate its position in the short- and medium-term stay market, and become a major player in the French private hospital sector.

Founded in 2005 through the formation of three clinics, C2S now operates 11 clinics and claims to be the eighth largest operator of private clinics in France. It operates medical, surgical and obstetric centres. The company employs 2,300 staff and the group generated a turnover of €158m in the financial year of 2016. C2S is headquartered in Paris.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• France
• Healthcare
• France
• Bridgepoint
• Eurazeo